Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Medicine (Baltimore). 2024 Sep 27;103(39):e39840. doi: 10.1097/MD.0000000000039840.
Endocrine disruptors are considered estrogenic disruptors, and recent researches suggested that they may have a link to the severity of asthma. We aim to validate the correlation between endocrine disruptors and various clinical measurements of asthma, depending on the menopausal status. A pilot case-control study was performed in female asthmatic patients who visited allergy clinic in SMG-SNU Boramae Medical Center. Medical information and the urinary concentrations of 4 endocrine disruptors on their first visit were collected and analyzed: bisphenol A, mono (2-ethyl-5-hydroxyhexyl) phthalate, mono (2-ethyl-5-oxohexyl) phthalate, and mono-n-butyl phthalate. A total of 35 female participants enrolled in the study, including 20 asthmatic patients and 15 healthy controls. The average concentrations of urinary endocrine disruptors in patient and control group did not demonstrate significant differences. Twenty asthmatic patients were divided into 2 groups according to their menstrual state. Using the Spearman rank correlation test in premenopausal asthmatic patients (n = 7), we found negative correlations between urinary concentration of mono-n-butyl phthalate and asthma control test score, as well as postbronchodilator forced expiratory flow at 25% to 75% of forced vital capacity (P-value = .007 and .04, respectively). In contrast, it did not show any correlation with asthma control test or postbronchodilator forced expiratory flow at 25% to 75% of forced vital capacity (P-value = 1.00 and .74, respectively) in postmenopausal group (n = 13). Endocrine disruptors might have an impact on the decline of small airway function and asthma management among premenopausal, but not postmenopausal, female asthmatic patients.
内分泌干扰物被认为是雌激素干扰物，最近的研究表明它们可能与哮喘的严重程度有关。我们旨在根据绝经状态验证内分泌干扰物与哮喘的各种临床测量之间的相关性。在 SMG-SNU 宝光医疗中心的过敏诊所就诊的女性哮喘患者中进行了一项试点病例对照研究。收集并分析了她们首次就诊时的医学信息和 4 种内分泌干扰物的尿液浓度：双酚 A、单（2-乙基-5-羟基己基）邻苯二甲酸酯、单（2-乙基-5-氧代己基）邻苯二甲酸酯和单丁基邻苯二甲酸酯。共有 35 名女性参与者入组研究，包括 20 名哮喘患者和 15 名健康对照者。患者组和对照组尿液内分泌干扰物的平均浓度无显著差异。20 名哮喘患者根据月经状态分为两组。在 7 名绝经前哮喘患者中使用 Spearman 秩相关检验，我们发现单丁基邻苯二甲酸酯的尿液浓度与哮喘控制测试评分以及支气管扩张后用力呼气流量在 25%至 75%用力肺活量之间呈负相关（P 值分别为.007 和.04）。相比之下，在 13 名绝经后患者中，它与哮喘控制测试或支气管扩张后用力呼气流量在 25%至 75%用力肺活量之间均无相关性（P 值分别为 1.00 和.74）。内分泌干扰物可能对绝经前女性哮喘患者小气道功能下降和哮喘管理产生影响，但对绝经后女性无影响。
